Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

by Ysios Capital

Aura Biosciences today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Inv...

Read more

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

by Ysios Capital

​Ysios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on th...

Read more

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Read more

Aura Biosciences Completes $40 Million Series D Financing

by Ysios Capital

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Anti-cancer drug could improve symptoms ...

by Universitat Autònoma de Barcelona (UAB)

It has been demonstrated in animal models the benefits of vorinostat a...

Photos Stream